Truist upgraded pain therapy developer Pacira BioSciences (NASDAQ:PCRX) to Hold from Sell on Thursday, noting that the company's management is "more likely" to settle a patent litigation with generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback